Table 1.
PsV neutralizing antibody titer elicited by B.1.1.7 monovalent, B.1.351 monovalent, and SCTV01C bivalent vaccines.
| Vaccines | Variants | D614G | VOC | VOI | VUM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B.1 | B.1.1.7 | B.1.351 | P.1 | B.1.617.2 | B.1.1.529 | C.37 | B.1.621 | B.1.526 | B.1.617.1 | B.1.429 | C.36.3 | B.1.618 | 20I/484Q | ||
| / | (Alpha) | (Beta) | (Gamma) | (Delta) | (Omicron) | (Lambda) | (Mu) | (Iota) | (Kappa) | (Epsilon) | / | / | / | ||
| B.1.1.7 Vaccine | NAT 50 | 2323 | 9412 | 489 | 563 | 328 | 139 | 1114 | 720 | 1194 | 490 | 840 | 563 | 1027 | 4040 |
| Fold Reduction a | 4.1 | 1.0 | 19.2 | 16.7 | 28.7 | 67.8 | 8.4 | 13.1 | 7.9 | 19.2 | 11.2 | 16.7 | 9.2 | 2.3 | |
| B.1.351 Vaccine | NAT 50 | 1511 | 2131 | 16,106 | 8644 | 1364 | 519 | 913 | 1726 | 1848 | 3071 | 2073 | 60 c | 2570 | 1574 |
| Fold Reduction b | 10.7 | 7.6 | 1.0 | 1.9 | 11.8 | 18.1 | 17.6 | 9.3 | 8.7 | 5.2 | 7.8 | 268.4 | 6.3 | 10.2 | |
| SCTV01C Bivalent Vaccine | NAT 50 | 6411 | 13,019 | 10,480 | 8745 | 3134 | 437 | 2892 | 2595 | 3324 | 4846 | 5761 | 1185 | 4365 | 3134 |
|
Fold Increase
(vs B.1.1.7 vac) |
2.8 | 1.4 | 21.4 | 15.5 | 9.6 | 3.1 | 2.6 | 3.6 | 2.8 | 9.9 | 6.9 | 2.1 | 4.2 | 0.8 | |
|
Fold Increase
(vs B.1.351 vac) |
4.2 | 6.1 | 0.7 | 1 | 2.3 | 0.8 | 3.2 | 1.5 | 1.8 | 1.6 | 2.8 | 19.8 | 1.7 | 2 | |
a, compared with NAT50 against the B.1.1.7 PsV. b, compared with NAT50 against the B.1.351 PsV. c, lower than the limit of detection (LOD, represented as a GMT of 60). VOC, variants of concern; VOI, variants of interest; VUM, variants under monitoring.